Home
/
ABBOTT LABORATORIES
/
Financials
/
Quarterly
ABBOTT LABORATORIES — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that ABBOTT LABORATORIES filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$11.37B
Oct 29, 2025
Q2
2025
Jun 30, 2025
$11.14B
Jul 30, 2025
Q1
2025
Mar 31, 2025
$10.36B
Apr 30, 2025
Q3
2025
Sep 30, 2024
$10.64B
Oct 29, 2025
Q2
2025
Jun 30, 2024
$10.38B
Jul 30, 2025
Q1
2025
Mar 31, 2024
$9.96B
Apr 30, 2025
Q3
2024
Sep 30, 2023
$10.14B
Oct 31, 2024
Q2
2024
Jun 30, 2023
$9.98B
Jul 31, 2024
Q1
2024
Mar 31, 2023
$9.75B
May 2, 2024
Q3
2023
Sep 30, 2022
$10.41B
Nov 1, 2023
Q2
2023
Jun 30, 2022
$11.26B
Aug 3, 2023
Q1
2023
Mar 31, 2022
$11.90B
May 4, 2023
Q3
2022
Sep 30, 2021
$10.93B
Nov 1, 2022
Q2
2022
Jun 30, 2021
$10.22B
Aug 2, 2022
Q1
2022
Mar 31, 2021
$10.46B
May 3, 2022
Q3
2021
Sep 30, 2020
$8.85B
Nov 3, 2021
Q2
2021
Jun 30, 2020
$7.33B
Aug 4, 2021
Q1
2021
Mar 31, 2020
$7.73B
May 5, 2021
Q3
2020
Sep 30, 2019
$8.08B
Nov 4, 2020
Q2
2020
Jun 30, 2019
$7.98B
Jul 29, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2017
Sep 30, 2017
$6.83B
Nov 2, 2017
Q2
2017
Jun 30, 2017
$6.64B
Aug 2, 2017
Q1
2017
Mar 31, 2017
$6.34B
May 3, 2017
Q3
2017
Sep 30, 2016
$5.30B
Nov 2, 2017
Q2
2017
Jun 30, 2016
$5.33B
Aug 2, 2017
Q1
2017
Mar 31, 2016
$4.89B
May 3, 2017
Q3
2016
Sep 30, 2015
$5.15B
Nov 3, 2016
Q2
2016
Jun 30, 2015
$5.17B
Aug 3, 2016
Q1
2016
Mar 31, 2015
$4.90B
May 4, 2016
Q3
2015
Sep 30, 2014
$5.08B
Nov 5, 2015
Q2
2015
Jun 30, 2014
$5.06B
Aug 4, 2015
Q1
2015
Mar 31, 2014
$4.76B
May 6, 2015
Q3
2014
Sep 30, 2013
$4.83B
Nov 6, 2014
Q2
2014
Jun 30, 2013
$5.45B
Aug 5, 2014
Q1
2014
Mar 31, 2013
$5.38B
May 7, 2014
Q3
2013
Sep 30, 2012
$5.26B
Nov 7, 2013
Q2
2013
Jun 30, 2012
$5.31B
Aug 6, 2013
Q1
2013
Mar 31, 2012
$5.28B
May 8, 2013
Q3
2012
Sep 30, 2011
$9.82B
Nov 7, 2012
Q2
2012
Jun 30, 2011
$9.62B
Aug 7, 2012
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$1.64B
Oct 29, 2025
Q2
2025
Jun 30, 2025
$1.78B
Jul 30, 2025
Q1
2025
Mar 31, 2025
$1.33B
Apr 30, 2025
Q3
2025
Sep 30, 2024
$1.65B
Oct 29, 2025
Q2
2025
Jun 30, 2024
$1.30B
Jul 30, 2025
Q1
2025
Mar 31, 2024
$1.23B
Apr 30, 2025
Q3
2024
Sep 30, 2023
$1.44B
Oct 31, 2024
Q2
2024
Jun 30, 2023
$1.38B
Jul 31, 2024
Q1
2024
Mar 31, 2023
$1.32B
May 2, 2024
Q3
2023
Sep 30, 2022
$1.44B
Nov 1, 2023
Q2
2023
Jun 30, 2022
$2.02B
Aug 3, 2023
Q1
2023
Mar 31, 2022
$2.45B
May 4, 2023
Q3
2022
Sep 30, 2021
$2.10B
Nov 1, 2022
Q2
2022
Jun 30, 2021
$1.19B
Aug 2, 2022
Q1
2022
Mar 31, 2021
$1.79B
May 3, 2022
Q3
2021
Sep 30, 2020
$1.23B
Nov 3, 2021
Q2
2021
Jun 30, 2020
$537.00M
Aug 4, 2021
Q1
2021
Mar 31, 2020
$564.00M
May 5, 2021
Q3
2020
Sep 30, 2019
$960.00M
Nov 4, 2020
Q2
2020
Jun 30, 2019
$1.01B
Jul 29, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$2.06B
Oct 29, 2025
Q2
2025
Jun 30, 2025
$2.05B
Jul 30, 2025
Q1
2025
Mar 31, 2025
$1.69B
Apr 30, 2025
Q3
2025
Sep 30, 2024
$1.86B
Oct 29, 2025
Q2
2025
Jun 30, 2024
$1.67B
Jul 30, 2025
Q1
2025
Mar 31, 2024
$1.39B
Apr 30, 2025
Q3
2024
Sep 30, 2023
$1.65B
Oct 31, 2024
Q2
2024
Jun 30, 2023
$1.54B
Jul 31, 2024
Q1
2024
Mar 31, 2023
$1.51B
May 2, 2024
Q3
2023
Sep 30, 2022
$1.77B
Nov 1, 2023
Q2
2023
Jun 30, 2022
$2.38B
Aug 3, 2023
Q1
2023
Mar 31, 2022
$2.91B
May 4, 2023
Q3
2022
Sep 30, 2021
$2.55B
Nov 1, 2022
Q2
2022
Jun 30, 2021
$1.39B
Aug 2, 2022
Q1
2022
Mar 31, 2021
$2.11B
May 3, 2022
Q3
2021
Sep 30, 2020
$1.50B
Nov 3, 2021
Q2
2021
Jun 30, 2020
$672.00M
Aug 4, 2021
Q1
2021
Mar 31, 2020
$758.00M
May 5, 2021
Q3
2020
Sep 30, 2019
$1.20B
Nov 4, 2020
Q2
2020
Jun 30, 2019
$1.21B
Jul 29, 2020